MR

Michael Rape

Professor and Head, Division of Molecular Therapeutics, UC Berkeley; Investigator, HHMI; Founder, Nurix Tx; Founder, Lyterian Tx

San Francisco Bay Area

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Education

Lists including Michael

AH
AE
AF
AJ

Based in SF

3077 people

AT
AS
AT
AH

All Series A Investors

14748 people

AM
AT
AS
AR

All Seed Investors

19691 people

Work Experience

LT
Lyterian Therapeutics

2022

  • Co-Founder

    2022

VT
Vicinitas Therapeutics

2022

  • Member, Scientific Advisory Board

    2022

Uo
University of California, Berkeley

2006

  • Head, Division of Molecular Therapeutics

    2022

  • Professor

    2006

TC
The Column Group

2021

  • iPartner

    2021

HH
Howard Hughes Medical Institute

2013

  • Investigator

    2013

MR
Monte Rosa Therapeutics

2020

  • Member, Scientific Advisory Board

    2020

NI
Nurix, Inc.

2012

  • Co-founder and member, Scientific Advisory Board

    2012